Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Kidney cancer in 2013

From molecular understanding to clinical advances

Nature Reviews Urology volume 11, pages 77–79 (2014)Cite this article

Subjects

Big data and computational biology brought to the forefront a number of potential actionable mutations and drug targets in clear cell renal cell carcinoma in 2013. As we continue to unravel the molecular underpinnings of tumorigenesis and progression, the clinical benefits will eventually be reaped.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: VHL loss induces reductive carboxylation.

References

  1. Kumar, R. et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br. J. Cancer 101, 1717–1723 (2009).

    Article  CAS  Google Scholar 

  2. Motzer, R. J. et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N. Engl. J. Med. 369, 722–731 (2013).

    Article  CAS  Google Scholar 

  3. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43–49 (2013).

  4. Linehan, W. M., Srinivasan, R. & Schmidt, L. S. The genetic basis of kidney cancer: a metabolic disease. Nat. Rev. Urol. 7, 277–285 (2010).

    Article  CAS  Google Scholar 

  5. Gameiro, P. A. et al. In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell. Metab. 17, 372–385 (2013).

    Article  CAS  Google Scholar 

  6. Wise, D. R. et al. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability. Proc. Natl Acad. Sci. USA 108, 19611–19616 (2011).

    Article  CAS  Google Scholar 

  7. Vanharanta, S. et al. Epigenetic expansion of VHL–HIF signal output drives multiorgan metastasis in renal cancer. Nat. Med. 19, 50–56 (2013).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Genito-urinary Oncology Service, Memorial Sloan–Kettering Cancer Center, 1275 York Avenue, New York, 10021, NY, USA

    Chung-Han Lee & Robert J. Motzer

Authors
  1. Chung-Han Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert J. Motzer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert J. Motzer.

Ethics declarations

Competing interests

R. J. Motzer has acted a consultant for Genentech and Pfizer and has received research funding from Genentech, GlaxoSmithKline and Novartis. C.-H. Lee declares no competing interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, CH., Motzer, R. From molecular understanding to clinical advances. Nat Rev Urol 11, 77–79 (2014). https://doi.org/10.1038/nrurol.2013.307

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2013.307

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer